- Home
- NXTC vs PLUR Comparison
NXTC vs PLUR Comparison
Compare NXTC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- PLUR
- Stock Information
- Founded
- NXTC 2015
- PLUR 2001
- Country
- NXTC United States
- PLUR Israel
- Employees
- NXTC N/A
- PLUR N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXTC Health Care
- PLUR Health Care
- Exchange
- NXTC Nasdaq
- PLUR Nasdaq
- Market Cap
- NXTC 24.6M
- PLUR 36.9M
- IPO Year
- NXTC 2019
- PLUR N/A
- Fundamental
- Price
- NXTC $9.27
- PLUR $4.07
- Analyst Decision
- NXTC Strong Buy
- PLUR Strong Buy
- Analyst Count
- NXTC 2
- PLUR 1
- Target Price
- NXTC $25.50
- PLUR $12.00
- AVG Volume (30 Days)
- NXTC 79.4K
- PLUR 10.2K
- Earning Date
- NXTC 11-04-2025
- PLUR 11-11-2025
- Dividend Yield
- NXTC N/A
- PLUR N/A
- EPS Growth
- NXTC N/A
- PLUR N/A
- EPS
- NXTC N/A
- PLUR N/A
- Revenue
- NXTC N/A
- PLUR $1,336,000.00
- Revenue This Year
- NXTC N/A
- PLUR $97.38
- Revenue Next Year
- NXTC N/A
- PLUR $293.97
- P/E Ratio
- NXTC N/A
- PLUR N/A
- Revenue Growth
- NXTC N/A
- PLUR 309.82
- 52 Week Low
- NXTC $2.69
- PLUR $3.33
- 52 Week High
- NXTC $19.20
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- NXTC 59.49
- PLUR 43.94
- Support Level
- NXTC $8.67
- PLUR $3.86
- Resistance Level
- NXTC $9.84
- PLUR $4.09
- Average True Range (ATR)
- NXTC 1.41
- PLUR 0.19
- MACD
- NXTC 0.12
- PLUR -0.02
- Stochastic Oscillator
- NXTC 44.39
- PLUR 43.16
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.